Daniel Harari
Daniel Harari
Senior Researcher in Medical Biology, The Weizmann Institute of Science
Verified email at weizmann.ac.il
Title
Cited by
Cited by
Year
Molecular mechanisms underlying ErbB2/HER2 action in breast cancer
D Harari, Y Yarden
Oncogene 19 (53), 6102-6114, 2000
7072000
Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor tyrosine kinase
D Harari, E Tzahar, J Romano, M Shelly, JH Pierce, GC Andrews, ...
Oncogene 18 (17), 2681-2689, 1999
3331999
Hsp90 recognizes a common surface on client kinases
A Citri, D Harari, G Shohat, P Ramakrishnan, J Gan, S Lavi, M Eisenstein, ...
Journal of biological chemistry 281 (20), 14361-14369, 2006
2272006
Ligand‐independent degradation of epidermal growth factor receptor involves receptor ubiquitylation and Hgs, an adaptor whose ubiquitin‐interacting motif targets ubiquitylation…
M Katz, K Shtiegman, P Tal‐Or, L Yakir, Y Mosesson, D Harari, Y Machluf, ...
Traffic 3 (10), 740-751, 2002
1622002
ErbB signaling regulates lineage determination of developing pancreatic islet cells in embryonic organ culture
MA Huotari, PJ Miettinen, J Palgi, T Koivisto, J Ustinov, D Harari, ...
Endocrinology 143 (11), 4437-4446, 2002
962002
Epigen, the last ligand of ErbB receptors, reveals intricate relationships between affinity and mitogenicity
BS Kochupurakkal, D Harari, A Di-Segni, G Maik-Rachline, L Lyass, ...
Journal of Biological Chemistry 280 (9), 8503-8512, 2005
942005
c-Cbl is a suppressor of the neu oncogene
G Levkowitz, S Oved, LN Klapper, D Harari, S Lavi, M Sela, Y Yarden
Journal of Biological Chemistry 275 (45), 35532-35539, 2000
812000
Stochastic receptor expression determines cell fate upon interferon treatment
D Levin, D Harari, G Schreiber
Molecular and cellular biology 31 (16), 3252-3266, 2011
802011
Receptor density is key to the alpha2/beta interferon differential activities
I Moraga, D Harari, G Schreiber, G Uz, S Pellegrini
Molecular and cellular biology 29 (17), 4778-4787, 2009
742009
Receptor density is key to the alpha2/beta interferon differential activities
I Moraga, D Harari, G Schreiber, G Uz, S Pellegrini
Molecular and cellular biology 29 (17), 4778-4787, 2009
742009
Hsp90 increases LIM kinase activity by promoting its homo-dimerization
R Li, J Soosairajah, D Harari, A Citri, J Price, HL Ng, CJ Morton, ...
The FASEB journal 20 (8), 1218-1220, 2006
632006
Type I interferons induce apoptosis by balancing cFLIP and caspase-8 independent of death ligands
A Apelbaum, G Yarden, S Warszawski, D Harari, G Schreiber
Molecular and cellular biology 33 (4), 800-814, 2013
432013
Enhanced in vivo efficacy of a type I interferon superagonist with extended plasma half-life in a mouse model of multiple sclerosis
D Harari, N Kuhn, R Abramovich, K Sasson, AL Zozulya, P Smith, ...
Journal of Biological Chemistry 289 (42), 29014-29029, 2014
392014
FGF plays a subtle role in oligodendrocyte maintenance in vivo
D Harari, D Finkelstein, O Bernard
Journal of neuroscience research 49 (4), 404-415, 1997
211997
Bridging the species divide: transgenic mice humanized for type-I interferon response
D Harari, R Abramovich, A Zozulya, P Smith, S Pouly, M Kster, H Hauser, ...
PloS one 9 (1), 2014
182014
Growth factor which acts through erb b-4 rtk
D Harari, Y Yarden
US Patent 7,094,882, 2006
132006
A robust type I interferon gene signature from blood RNA defines quantitative but not qualitative differences between three major IFNβ drugs in the treatment of multiple sclerosis
D Harari, I Orr, R Rotkopf, SE Baranzini, G Schreiber
Human molecular genetics 24 (11), 3192-3205, 2015
102015
Polynucleotides encoding a novel growth factor which acts through ErbB-4 kinase receptor tyrosine
D Harari, Y Yarden
US Patent 6,544,759, 2003
82003
Rescue of an infertile transgenic line by ovarian transplantation
D Harari, O Bernard, JM Shaw
Transgenics, 143-151, 1997
81997
Fine tuning of a type 1 interferon antagonist
V Urin, D Levin, N Sharma, D Harari, G Schreiber
PloS one 10 (7), 2015
72015
The system can't perform the operation now. Try again later.
Articles 1–20